(Q1)Jan 31, 2024 | (FY)Oct 31, 2023 | (Q4)Oct 31, 2023 | (Q3)Jul 31, 2023 | (Q2)Apr 30, 2023 | (Q1)Jan 31, 2023 | (FY)Oct 31, 2022 | (Q4)Oct 31, 2022 | (Q3)Jul 31, 2022 | (Q2)Apr 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 0.47%-502.54K | -235.38%-3.17M | -938.99%-1.24M | 10.95%-518.35K | -322.13%-911.12K | -71.19%-504.9K | -182.71%-945.48K | 147.39K | -582.1K | -215.84K |
Net income from continuing operations | 80.35%-228.97K | -970.55%-5.16M | -334.64%-844.25K | -378.49%-533.88K | -1,383.41%-2.61M | -110.42%-1.17M | -194.17%-481.57K | --359.81K | ---111.58K | ---176.09K |
Operating gains losses | ---- | 72.45%85.7K | -101.02%-433 | -1,612.23%-9.27K | 68.75%4.35K | 2,246.12%91.05K | 3,314.29%49.69K | --42.62K | --613 | --2.58K |
Depreciation and amortization | 1.78%146.41K | 202.63%575.3K | 148.84%150.95K | 192.62%139.91K | 235.42%140.6K | 262.26%143.85K | 324.20%190.1K | --60.66K | --47.81K | --41.92K |
Asset impairment expenditure | ---- | 9,630.35%280.82K | ---- | ---- | ---- | ---- | --2.89K | ---- | ---- | ---- |
Remuneration paid in stock | 524.63%30.84K | 2,443.72%502.38K | 970.37%52.86K | 999.37%54.28K | 7,804.33%390.32K | 0.00%4.94K | -37.69%19.75K | --4.94K | --4.94K | --4.94K |
Other non cashItems | 112.56%12.19K | 487.04%1.56M | 101.78%6.95K | 26.49%-27.76K | 12,996.11%1.68M | -896.52%-97.07K | -1,422.86%-402.98K | ---390.22K | ---37.76K | --12.81K |
Change In working capital | -189.47%-463K | -215.28%-1.02M | -1,424.68%-883.49K | 70.87%-141.63K | -401.86%-511.85K | 161.26%517.49K | 66.01%-323.35K | --66.69K | ---486.13K | ---101.99K |
-Change in receivables | -242.27%-292.94K | -244.56%-590.12K | -297.58%-379.45K | 91.29%-47.75K | -118.91%-368.83K | -41.75%205.91K | 53.51%-171.27K | --192.05K | ---548.32K | ---168.48K |
-Change in inventory | -200.19%-187.15K | 481.04%325.79K | -55.34%141.84K | -1,011.36%-564.63K | 535.31%561.79K | 155.60%186.79K | 72.29%-85.5K | --317.58K | --61.96K | ---129.05K |
-Change in prepaid assets | 72.24%-38.57K | -32.72%-161.16K | -321.05%-348.49K | 59.59%292.78K | -59.14%33.48K | 54.31%-138.93K | -201.06%-121.43K | ---82.77K | --183.47K | --81.95K |
-Change in payables and accrued expense | -55.71%81.52K | -101.48%-2.13K | 116.08%35.36K | 782.44%384.71K | -447.02%-606.27K | -25.06%184.07K | -22.08%144.04K | ---219.91K | ---56.37K | --174.71K |
-Change in other current assets | ---- | --0 | --0 | --0 | ---- | ---- | 135.16%12.31K | ---1 | --0 | --0 |
-Change in other working capital | -132.46%-25.86K | -483.11%-591.85K | -137.23%-332.74K | -62.96%-206.74K | -116.05%-132.03K | -64.87%79.66K | 81.35%-101.5K | ---140.26K | ---126.86K | ---61.11K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 0.47%-502.54K | -235.38%-3.17M | -938.99%-1.24M | 10.95%-518.35K | -322.13%-911.12K | -71.19%-504.9K | -182.71%-945.48K | --147.39K | ---582.1K | ---215.84K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 115.81%5.95K | 243.40%1.17M | 92.48%-44.01K | 19.55%-70.87K | 31,198.34%1.33M | 73.38%-37.63K | -713.91%-819.03K | -585.31K | -88.08K | -4.27K |
Net PPE purchase and sale | -62.56%-21.47K | 30.63%-148.96K | -6,228.04%-60.94K | 27.95%-55.53K | -515.64%-19.29K | 90.66%-13.2K | -124.56%-214.75K | ---963 | ---77.06K | --4.64K |
Net intangibles purchas and sale | 63.63%-8.88K | -43.72%-36.04K | 429.14%16.93K | -39.18%-15.34K | -48.24%-13.21K | ---24.43K | -401.60%-25.08K | ---5.15K | ---11.02K | ---8.91K |
Net business purchase and sale | ---- | 334.71%1.36M | --0 | --0 | ---- | ---- | ---579.21K | ---579.21K | --0 | ---- |
Net other investing changes | --36.3K | --2 | --1 | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 115.81%5.95K | 243.40%1.17M | 92.48%-44K | 19.55%-70.86K | 31,198.34%1.33M | 73.38%-37.63K | -713.91%-819.03K | ---585.31K | ---88.08K | ---4.27K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 20.05%909.05K | 998.40%5.22M | -51.29%-50.99K | 648.01%2.5M | 837.15%2.02M | 224.71%757.2K | -642.04%-580.95K | -33.7K | 333.61K | -273.7K |
Net issuance payments of debt | 20.05%909.05K | -425.93%-3.06M | -136.46%-2.17M | 12.45%1.37M | -999.68%-3.01M | 224.71%757.2K | -642.04%-580.95K | ---919.31K | --1.22M | ---273.7K |
Net common stock issuance | ---- | --8.67M | --0 | --3.69M | ---- | ---- | --0 | --0 | --0 | ---- |
Proceeds from stock option exercised by employees | ---- | --77.6K | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- |
Net other financing activities | ---- | ---474.34K | --2.12M | ---2.56M | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 20.05%909.05K | 998.40%5.22M | -51.29%-50.99K | 648.01%2.5M | 837.15%2.02M | 224.71%757.2K | -642.04%-580.95K | ---33.7K | --333.61K | ---273.7K |
Net cash flow | ||||||||||
Beginning cash position | 131.57%773.37K | -2,258.06%-2.45M | 206.44%2.1M | 112.11%198.78K | -94.77%-2.23M | -2,258.06%-2.45M | -146.37%-103.87K | ---1.98M | ---1.64M | ---1.15M |
Current changes in cash | 92.13%412.46K | 237.40%3.22M | -182.34%-1.33M | 666.34%1.91M | 592.79%2.43M | 120.57%214.67K | -615.34%-2.35M | ---471.62K | ---336.58K | ---493.81K |
End cash Position | 153.07%1.19M | 131.57%773.37K | 131.57%773.37K | 206.44%2.1M | 112.11%198.78K | -94.77%-2.23M | -2,258.06%-2.45M | ---2.45M | ---1.98M | ---1.64M |
Free cash from | 1.78%-532.89K | -183.13%-3.36M | -1,006.41%-1.28M | 12.08%-589.22K | -328.71%-943.62K | -24.35%-542.53K | -172.45%-1.19M | --141.28K | ---670.19K | ---220.11K |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.